4‐1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4‐1BB agonists

• Yuji Uehara,
• Shumei Kato,
• Daisuke Nishizaki,
• Hirotaka Miyashita,
• Suzanna Lee,
• Mary K. Nesline,
• Sarabjot Pabla,
• Jeffrey M. Conroy,
• Paul DePietro,
• Heidi Ko,
• Jason K. Sicklick,
• Razelle Kurzrock

Affiliations

Yuji Uehara

Department of Thoracic Oncology and Respiratory Medicine Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo Japan

Shumei Kato

Center for Personalized Cancer Therapy and Division of Hematology and Oncology Department of Medicine University of California San Diego Moores Cancer Center La Jolla California United States

Daisuke Nishizaki

Center for Personalized Cancer Therapy and Division of Hematology and Oncology Department of Medicine University of California San Diego Moores Cancer Center La Jolla California United States

Hirotaka Miyashita

Dartmouth Cancer Center Hematology and Medical Oncology Lebanon New Hampshire United States

Suzanna Lee

Center for Personalized Cancer Therapy and Division of Hematology and Oncology Department of Medicine University of California San Diego Moores Cancer Center La Jolla California United States

Mary K. Nesline

Labcorp Oncology Durham North Carolina United States

Sarabjot Pabla

OmniSeq Incorporation Buffalo New York United States

Jeffrey M. Conroy

OmniSeq Incorporation Buffalo New York United States

Paul DePietro

OmniSeq Incorporation Buffalo New York United States

Heidi Ko

Labcorp Oncology Durham North Carolina United States

Jason K. Sicklick

Division of Surgical Oncology Department of Surgery Center for Personalized Cancer Therapy University of California San Diego La Jolla California United States

Razelle Kurzrock

Medical College of Wisconsin Cancer Center and Genomic Sciences and Precision Medicine Center Medical College of Wisconsin Milwaukee Wisconsin United States